Congratulations to Jommel Macaraeg for being selected by American Society of Hematology to receive the 2026 ASH Graduate Hematology Award, part of ASH’s investment in research and the next generation of hematologists!
#ASHAwards  #Fight4Hematology
Caner Saygin, MD
https://ow.ly/ANRZ50Z6XMn
I was very inspired by the @abc7chicago.bsky.social @leukemiaresearch.bsky.social Gibbons 5K Run Event this morning!
It was a blast to engage with our patients, families and friends to discuss leukemia research and raise money for this critical mission.
abc7chicago.com/post/32nd-an...
aacrjournals.org/bloodcancerd...
How should we incorporate molecular data in treatment decisions for ALL?
It is time to pay more attention to genetic heterogeneity of adult ALL before we decide therapy.
Targeted therapies are rapidly emerging, and replacing chemo in ALL.
Our review at Blood Cancer Discovery is out today! Link👇
We are very excited to share our work investigating menin inhibition in T-ALL, led by Kate Shimamoto and Arda Karaoglu, just published in Mol Cancer Therapeutics.
We found that high p-MEF2C S222 can predict menin inhibitor response, better than HOX gene expression levels, in T-ALL. rb.gy/oroosm
very cool work led by @canersaygin.bsky.social lab looking at the potential for targeting menin in T-cell ALL!
aacrjournals.org/mct/article/...
In a recent study, Caner Saygin, MD and team examined a large group of adults with a rare, aggressive form of leukemia called TP53-mutant ALL and found key genetic changes that guide doctors to predict which pts may face more serious outcomes. @uchicagomedicine.bsky.social
https://ow.ly/cFsz50YgL2s
InO + TKI has robust activity but limited toxicity when drugs are given sequentially. Great option for older adults with Ph+ ALL in frontline.
Our NCI study of HMA +/- Iadademstat is enrolling briskly for patients with HMA-naive accelerated/blast phase MPNs and overlap syndromes!
www.cancer.gov/research/par...
Congrats @herranzlab.bsky.social! Very cool story.
AbstractAcute lymphoblastic leukemia (ALL) management is evolving from a generalized approach toward a precision medicine paradigm driven by molecular heterogeneity. This review highlights how genomic...
Got to present our Ph+ ALL TKI plus inotuzumab study at #ASH25! Highlights:
-all patients achieved MR4 or NGS negativity
-VOD seen with initial schema, updated schema splitting InO and TKI had no VOD
-80% OS and 76% EFS with no CNS relapse, one systemic relapse, and no allo-HCT
